Shilpa Medicare has informed that the Board of Directors, at their meeting held on December 26, 2016, allotted 3,025,000, equity share of Re 1 each at a premium of Rs 569 per share in the name of TA FII Investors, IFS Court, Bank Street, Twenty Eight, Cybercity Ebene 72201, Mauritius pursuant to the resolution passed by the shareholders at their Extra-Ordinary General Meeting held on 26th December, 2016 and in-principal approvals received from BSE (Dt:8th December, 2016) National Stock Exchange of India (Dt.23rd December, 2016). The Company has further intimate that Naresh Patwari has been co-opted as an Additional (non-executive and non-independent) Director of the Company, being the nominee of TA FII Investors with effect from this date, subject to regularization by shareholders at the ensuing annual general meeting of the Company in accordance with the requirements of the Companies Act, 2013.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: